Can determination of circulating endothelial cells and serum caspase-cleaved CK18 Predict for response and survival in patients with advanced non-small-cell lung cancer receiving endostatin and paclitaxel-carboplatin chemotherapy?: a retrospective study
Introduction: Early prediction of the efficacy of a combination of an antiangiogenic drug with cytotoxic chemotherapy is a significant challenge. In that regard, circulating endothelial cells (CECs) and cytokeratins (CKs) seem to reflect their roles in both tumor angiogenesis and tumor cell death.Me...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2015
|
| In: |
Journal of thoracic oncology
Year: 2012, Volume: 7, Issue: 12, Pages: 1781-1789 |
| ISSN: | 1556-1380 |
| DOI: | 10.1097/JTO.0b013e3182725fe0 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1097/JTO.0b013e3182725fe0 Verlag, kostenfrei, Volltext: http://www.sciencedirect.com/science/article/pii/S1556086415331610 
|
| Author Notes: | Tian-Qing Chu, Hao Ding, David H. Garfield, Ai-Qin Gu, Jun Pei, Wei-Dong Du and Bao-Hui Han |
| Summary: | Introduction: Early prediction of the efficacy of a combination of an antiangiogenic drug with cytotoxic chemotherapy is a significant challenge. In that regard, circulating endothelial cells (CECs) and cytokeratins (CKs) seem to reflect their roles in both tumor angiogenesis and tumor cell death.Methods: Patients with advanced, previously untreated non-small-cell lung cancer were randomly assigned to an endostatin treatment group (paclitaxel + carboplatin + endostatin) and a control group (paclitaxel + carboplatin + placebo). A total of 122 patients were evaluated, of whom 107 had measurements of blood CECs, CK8, caspase-cleaved CK18 (ccCK18), and uncleaved CK18 (CK18) before and at weeks 3 and 6 of treatment, respectively.Results: Higher baseline CECs in patients with a tumor response (partial remission + stable disease, p = 0.002 for the entire group; p = 0.000 for the treatment group) were observed. The number of CECs decreased significantly after endostatin treatment (p = 0.000), whereas CK levels increased. Increased levels of ccCK18 and CK18, but not CK8, reached significance (p = 0.001 and p = 0.048, respectively) when compared with the baseline. Tumor response showed a strong correlation with reduction of CECs (p = 0.000) and increase of ccCK18 (p = 0.040) after endostatin therapy. Cutoff values of changes of CECs and ccCK18 for prediction of survival were 0.58/μl and 19.6 ng/ml, respectively. Reduction of CECs and increase of ccCK18 significantly correlated with longer median survival (p = 0.013 and p = 0.016 for progression-free survival; p = 0.009 and p = 0.012 for overall survival, respectively).Conclusions: CECs and CKs could be biomarkers for selecting patients with non-small-cell lung cancer who will benefit from treatment with endostatin in combination with paclitaxel plus carboplatin. |
|---|---|
| Item Description: | Available online 20 November 2015 Gesehen am 23.07.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1556-1380 |
| DOI: | 10.1097/JTO.0b013e3182725fe0 |